Publications

Export 19 results:
Author [ Title(Desc)] Type Year
Filters: Author is Lam, Raymond W  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
McGirr A, Berlim M, Bond DJ, Chan PY, Yatham LN, Lam RW.  2017.  Adjunctive ketamine in electroconvulsive therapy: updated systematic review and meta-analysis.. Br J Psychiatry. 210(6):403-407.
Yrondi A, Fiori LM, Frey BN, Lam RW, Macqueen GM, Milev R, Müller DJ, Foster JA, Kennedy SH, Turecki G.  2019.  Association between side effects and blood microRNA expression levels and their targeted pathways in patients with major depressive disorder treated by a selective serotonin reuptake inhibitor, escitalopram: a CAN-BIND-1 report.. Int J Neuropsychopharmacol.
Yrondi A, Fiori LM, Nogovitsyn N, Hassel S, Théroux JFrançois, Aouabed Z, Frey BN, Lam RW, Milev R, Müller DJ et al..  2021.  Association between the expression of lncRNA BASP-AS1 and volume of right hippocampal tail moderated by episode duration in major depressive disorder: a CAN-BIND 1 report.. Transl Psychiatry. 11(1):469.
C
Kennedy SH, Lam RW, McIntyre RS, S Tourjman V, Bhat V, Blier P, Hasnain M, Jollant F, Levitt AJ, Macqueen GM et al..  2016.  Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments.. Can J Psychiatry. 61(9):540-60.
Baskaran A, Farzan F, Milev R, Brenner CA, Alturi S, McAndrews MPat, Blier P, Evans K, Foster JA, Frey BN et al..  2017.  The comparative effectiveness of electroencephalographic indices in predicting response to escitalopram therapy in depression: A pilot study.. J Affect Disord. 227:542-549.
Desan PH, Weinstein AJ, Michalak EE, Tam EM, Meesters Y, Ruiter MJ, Horn E, Telner J, Iskandar H, Boivin DB et al..  2007.  A controlled trial of the Litebook light-emitting diode (LED) light therapy device for treatment of Seasonal Affective Disorder (SAD).. BMC Psychiatry. 7:38.
D
Lam RW, Milev R, Rotzinger S, Andreazza AC, Blier P, Brenner C, Daskalakis ZJ, Dharsee M, Downar J, Evans KR et al..  2016.  Discovering biomarkers for antidepressant response: protocol from the Canadian biomarker integration network in depression (CAN-BIND) and clinical characteristics of the first patient cohort.. BMC Psychiatry. 16:105.
E
Wang JL, Patten SB, Lam RW, Attridge M, Ho K, Schmitz N, Marchand A, Lashewicz BM.  2016.  The Effects of an E-Mental Health Program and Job Coaching on the Risk of Major Depression and Productivity in Canadian Male Workers: Protocol for a Randomized Controlled Trial.. JMIR Res Protoc. 5(4):e218.
G
Marshe VS, Maciukiewicz M, Hauschild A-C, Islam F, Qin L, Tiwari AK, Sibille E, Blumberger DM, Karp JF, Flint AJ et al..  2021.  Genome-wide analysis suggests the importance of vascular processes and neuroinflammation in late-life antidepressant response.. Transl Psychiatry. 11(1):127.
H
Suh JSu, Fiori LM, Ali M, Harkness KL, Ramonas M, Minuzzi L, Hassel S, Strother SC, Zamyadi M, Arnott SR et al..  2021.  Hypothalamus volume and DNA methylation of stress axis genes in major depressive disorder: A CAN-BIND study report.. Psychoneuroendocrinology. 132:105348.
I
Ju C, Fiori LM, Belzeaux R, Théroux J-F, Chen GGang, Aouabed Z, Blier P, Farzan F, Frey BN, Giacobbe P et al..  2019.  Integrated genome-wide methylation and expression analyses reveal functional predictors of response to antidepressants.. Transl Psychiatry. 9(1):254.
M
Caspani G, Turecki G, Lam RW, Milev RV, Frey BN, Macqueen GM, Müller DJ, Rotzinger S, Kennedy SH, Foster JA et al..  2021.  Metabolomic signatures associated with depression and predictors of antidepressant response in humans: A CAN-BIND-1 report.. Commun Biol. 4(1):903.
Lopez JPablo, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C et al..  2017.  MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes.. Nat Commun. 8:15497.
P
Belzeaux R, Fiori LM, Lopez JPablo, Boucekine M, Boyer L, Blier P, Farzan F, Frey BN, Giacobbe P, Lam RW et al..  2019.  Predicting Worsening Suicidal Ideation With Clinical Features and Peripheral Expression of Messenger RNA and MicroRNA During Antidepressant Treatment.. J Clin Psychiatry. 80(3)
Wang JL, Lam RW, Ho K, Attridge M, Lashewicz BM, Patten SB, Marchand A, Aiken A, Schmitz N, Gundu S et al..  2016.  Preferred Features of E-Mental Health Programs for Prevention of Major Depression in Male Workers: Results From a Canadian National Survey.. J Med Internet Res. 18(6):e132.
R
Bhat V, Leong K, Lee J, Voineskos D, Daskalakis ZJ, Lam RW, Jollant F.  2014.  Research-track programs for residents in psychiatry: a review of literature and a report of 3 Canadian experiences.. Can J Psychiatry. 59(5):268-75.
S
Uher R, Frey BN, Quilty LC, Rotzinger S, Blier P, Foster JA, Müller DJ, Ravindran AV, Soares CN, Turecki G et al..  2020.  Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.. J Clin Psychiatry. 81(4)
McGirr A, Berlim M, Bond DJ, Neufeld NH, Chan PY, Yatham LN, Lam RW.  2015.  A systematic review and meta-analysis of randomized controlled trials of adjunctive ketamine in electroconvulsive therapy: efficacy and tolerability.. J Psychiatr Res. 62:23-30.
T
Fiori LM, Orri M, Aouabed Z, Théroux JFrançois, Lin R, Nagy C, Frey BN, Lam RW, Macqueen GM, Milev R et al..  2021.  Treatment-emergent and trajectory-based peripheral gene expression markers of antidepressant response.. Transl Psychiatry. 11(1):439.